AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)
Alnylam Q3 2026 revenue rises 17% to $1.46 billion; operating income falls 6%
Alnylam reported third quarter 2026 total revenues of $1.46 billion, up 17% from a year earlier, led by net product revenues of $1.29 billion, up 52%. GAAP net income reached $2.17 billion, or $15.72 per diluted share, but that figure includes a $1.9 billion income tax benefit, while GAAP income from operations fell 6% to $345.8 million. The company reiterated its full-year 2026 guidance.
Key points
- Total revenues were $1,458.1 million versus $1,249.0 million in Q3 2025, up 17%.
- Total net product revenues were $1,292 million, up 52%, with Total TTR net product revenues at $1,150 million.
- GAAP income from operations was $345.8 million, down 6% from $368.0 million, while GAAP diluted EPS was $15.72 versus $2.14, helped by a $1.9 billion tax benefit.
- Full-year 2026 total net product revenues guidance of $4,700 million to $5,100 million was reiterated.
The filing
CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECOct 29, 2026, 8:16 AM ET
Accession number0001178670-26-000074
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.